Register for our free email digests:
Generics
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
First Sabril Rival Sees FDA Deliver On Prioritizing Competition
Prioritizing the approval of generics of medicines with little or no competition has been a key part of the FDA’s efforts to support access and reduce costs to patients; the agency has just granted Teva approval for the first generic version of Lundbeck’s Sabril (vigabatrin) 500mg tablets.
European Council Brings SPC Manufacturing Waiver A Step Closer
A proposed SPC manufacturing waiver – which would allow generic and biosimilar manufacturing within Europe during the SPC period – has taken a step closer to being realized after the European Council approved a mandate for negotiations with the European Parliament. However, it remains uncertain whether key elements desired by the off-patent industry will fall into place.
Wockhardt Wins Review Of Ban On Indian Combination
Remodulin And Revlimid Rivals Join France’s Répertoire
Almost 20 new generic groups – including rivals to Flecaine, Inegy, Remodulin and Revlimid – have been added to France’s répertoire of generic equivalents following the latest update by local medicines agency ANSM.
Court Clears Teva After At-Risk Budesonide Entry
Sandoz’ Hexal Avoids German Fulvestrant Use Patent
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.